Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025
Monte Rosa Therapeutics (Nasdaq: GLUE) has announced an upcoming pipeline update and financial results presentation scheduled for March 20, 2025. The presentation will feature clinical results from two key studies:
1. Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader MRT-6160
2. Phase 1/2 study of MRT-2359 in MYC-driven solid tumors
The company will host a conference call and webcast at 8:00 a.m. ET to discuss these clinical outcomes along with their fourth quarter and full year 2024 financial results. The presentation will be accessible through Monte Rosa's website, with a recording available for 30 days afterward.
Monte Rosa Therapeutics (Nasdaq: GLUE) ha annunciato un prossimo aggiornamento sul pipeline e una presentazione dei risultati finanziari programmata per 20 marzo 2025. La presentazione includerà i risultati clinici di due studi chiave:
1. Studio di Fase 1 SAD/MAD del degrader molecolare MRT-6160 diretto da VAV1
2. Studio di Fase 1/2 di MRT-2359 in tumori solidi guidati da MYC
La società ospiterà una conferenza telefonica e un webcast alle 8:00 a.m. ET per discutere di questi risultati clinici insieme ai risultati finanziari del quarto trimestre e dell'intero anno 2024. La presentazione sarà accessibile attraverso il sito web di Monte Rosa, con una registrazione disponibile per 30 giorni dopo.
Monte Rosa Therapeutics (Nasdaq: GLUE) ha anunciado una próxima actualización del pipeline y una presentación de resultados financieros programada para el 20 de marzo de 2025. La presentación contará con resultados clínicos de dos estudios clave:
1. Estudio de Fase 1 SAD/MAD del degradador molecular MRT-6160 dirigido por VAV1
2. Estudio de Fase 1/2 de MRT-2359 en tumores sólidos impulsados por MYC
La compañía realizará una conferencia telefónica y un webcast a las 8:00 a.m. ET para discutir estos resultados clínicos junto con los resultados financieros del cuarto trimestre y del año completo 2024. La presentación será accesible a través del sitio web de Monte Rosa, con una grabación disponible durante 30 días después.
몬테 로사 테라퓨틱스 (Nasdaq: GLUE)는 2025년 3월 20일로 예정된 파이프라인 업데이트 및 재무 결과 발표를 발표했습니다. 발표에서는 두 가지 주요 연구의 임상 결과가 포함됩니다:
1. VAV1에 의해 유도된 분자 접착제 분해제 MRT-6160의 1상 SAD/MAD 연구
2. MYC에 의해 구동되는 고형 종양에서의 MRT-2359의 1/2상 연구
회사는 동부 표준시 8:00 a.m.에 이러한 임상 결과와 2024년 4분기 및 전체 연도 재무 결과에 대해 논의하기 위한 전화 회의 및 웹캐스트를 개최합니다. 발표는 몬테 로사의 웹사이트를 통해 접근 가능하며, 이후 30일 동안 녹음이 제공됩니다.
Monte Rosa Therapeutics (Nasdaq: GLUE) a annoncé une prochaine mise à jour de son pipeline et une présentation des résultats financiers prévue pour le 20 mars 2025. La présentation mettra en avant les résultats cliniques de deux études clés :
1. Étude de Phase 1 SAD/MAD du dégradateur moléculaire MRT-6160 dirigé par VAV1
2. Étude de Phase 1/2 de MRT-2359 dans les tumeurs solides dirigées par MYC
La société organisera une conférence téléphonique et un webcast à 8:00 a.m. ET pour discuter de ces résultats cliniques ainsi que de ses résultats financiers du quatrième trimestre et de l'année entière 2024. La présentation sera accessible via le site Web de Monte Rosa, avec un enregistrement disponible pendant 30 jours après.
Monte Rosa Therapeutics (Nasdaq: GLUE) hat ein bevorstehendes Update zur Pipeline und eine Präsentation der Finanzergebnisse für den 20. März 2025 angekündigt. Die Präsentation wird klinische Ergebnisse aus zwei wichtigen Studien umfassen:
1. Phase 1 SAD/MAD-Studie des VAV1-gesteuerten molekularen Kleber-Abbaus MRT-6160
2. Phase 1/2-Studie von MRT-2359 bei MYC-gesteuerten soliden Tumoren
Das Unternehmen wird um 8:00 a.m. ET eine Telefonkonferenz und einen Webcast abhalten, um diese klinischen Ergebnisse sowie die Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 zu besprechen. Die Präsentation wird über die Website von Monte Rosa zugänglich sein, mit einer Aufzeichnung, die 30 Tage lang verfügbar ist.
- None.
- None.
Company to present clinical results from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader MRT-6160 and Phase 1/2 study of MRT-2359 in MYC-driven solid tumors
Conference call and webcast planned for 8 a.m. ET on March 20, 2025
BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will present a pipeline update including clinical results from its Phase 1 SAD/MAD study of the VAV1-directed MGD MRT-6160 and its Phase 1/2 study of MRT-2359 in MYC-driven solid tumors. A conference call and webcast are planned for Thursday, March 20, 2025, at 8:00 a.m. ET. The Company will also report its fourth quarter and full year 2024 financial results and business highlights on the same day.
A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com. Registration for the conference call is available at the following link. An archived version of the webcast will be made available for 30 days following the presentation.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.
Investors
Andrew Funderburk
ir@monterosatx.com
Media
Cory Tromblee, Scient PR
media@monterosatx.com
FAQ
When will Monte Rosa Therapeutics (GLUE) release its Q4 and full year 2024 financial results?
What clinical trial results will GLUE present in their March 2025 pipeline update?
How can investors access Monte Rosa's (GLUE) March 20, 2025 presentation?
How long will GLUE's March 2025 pipeline update webcast be available?
